Scholarlink

Background <p>The systemic inflammation response index (SIRI) is an emerging inflammation-immune indicator calculated from counts of neutrophils, monocytes, and lymphocytes. The potential prognostic value of SIRI in various tumors has been reported in several studies. However, updated and comprehensive evidence regarding its prognostic value in lung cancer (LC) remains insufficient. This study, through a systematic review and meta-analysis, intends to comprehensively analyze the relationship of SIRI with overall survival (OS) and progression-free survival (PFS) among individuals experiencing LC.</p> Methods <p>Cochrane Library, Web of Science, Embase, and PubMed were systematically searched from the commencement of the databases to October 2025. Cohort studies reporting the relation of SIRI with OS or PFS were included. Hazard ratios (HRs) alongside their 95% confidence intervals (CIs) were obtained, and a random-effects model was employed for data synthesis. Subgroup analysis, sensitivity analysis, and assessment of publication bias were conducted to evaluate the robustness of the findings.</p> Results <p>In total, 27 studies involving 6195 patients with LC were incorporated into this meta-analysis, which revealed that high SIRI levels were significantly associated with poorer OS (HR = 1.83, 95% CI 1.58–2.13) and PFS (HR = 1.53, 95% CI 1.31–1.79). Differences in age, region, and cutoff value for SIRI were identified as the primary sources of heterogeneity. The sensitivity analysis indicated stable results, while the Egger’s test demonstrated publication bias.</p> Conclusion <p>A higher SIRI level is significantly associated with adverse survival outcomes among individuals suffering from LC. As a simple and low-cost hematological marker, SIRI is potentially applied in the risk stratification and prognosis assessment of LC. In the future, prospective studies based on multicenter data and with a larger sample size, and a unified cutoff standard for SIRI are warranted to further corroborate the clinical utility of SIRI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between the systemic inflammation response index and prognosis in lung cancer: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2026年5月4日

查看全文
  • Tongtong Chu,
  • Xiuxi Li,
  • Lijuan Shan,
  • Chunshan Zhao

摘要

Background

The systemic inflammation response index (SIRI) is an emerging inflammation-immune indicator calculated from counts of neutrophils, monocytes, and lymphocytes. The potential prognostic value of SIRI in various tumors has been reported in several studies. However, updated and comprehensive evidence regarding its prognostic value in lung cancer (LC) remains insufficient. This study, through a systematic review and meta-analysis, intends to comprehensively analyze the relationship of SIRI with overall survival (OS) and progression-free survival (PFS) among individuals experiencing LC.

Methods

Cochrane Library, Web of Science, Embase, and PubMed were systematically searched from the commencement of the databases to October 2025. Cohort studies reporting the relation of SIRI with OS or PFS were included. Hazard ratios (HRs) alongside their 95% confidence intervals (CIs) were obtained, and a random-effects model was employed for data synthesis. Subgroup analysis, sensitivity analysis, and assessment of publication bias were conducted to evaluate the robustness of the findings.

Results

In total, 27 studies involving 6195 patients with LC were incorporated into this meta-analysis, which revealed that high SIRI levels were significantly associated with poorer OS (HR = 1.83, 95% CI 1.58–2.13) and PFS (HR = 1.53, 95% CI 1.31–1.79). Differences in age, region, and cutoff value for SIRI were identified as the primary sources of heterogeneity. The sensitivity analysis indicated stable results, while the Egger’s test demonstrated publication bias.

Conclusion

A higher SIRI level is significantly associated with adverse survival outcomes among individuals suffering from LC. As a simple and low-cost hematological marker, SIRI is potentially applied in the risk stratification and prognosis assessment of LC. In the future, prospective studies based on multicenter data and with a larger sample size, and a unified cutoff standard for SIRI are warranted to further corroborate the clinical utility of SIRI.